Welcome to our dedicated page for In8Bio SEC filings (Ticker: INAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IN8bio, Inc. (Nasdaq: INAB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta (γδ) T cell therapies and engagers for cancer and autoimmune diseases, and its filings offer structured insight into this development activity and its status as a Nasdaq-listed issuer.
IN8bio uses Form 8-K current reports to announce material events such as clinical data updates, preclinical presentations and financial results. For example, the company has filed 8-Ks referencing presentations of INB-200 and INB-400 glioblastoma data at the Society for Neuro-Oncology (SNO) Annual Meeting, new preclinical data from its INB-619 γδ T cell engager program at the American College of Rheumatology (ACR) Convergence Meeting, and quarterly financial results press releases. Another 8-K documents Nasdaq’s confirmation that IN8bio regained compliance with the minimum bid price listing rule, and reiterates that its common stock trades on The Nasdaq Stock Market LLC under the symbol INAB.
Through IN8bio’s periodic reports and exhibits referenced in 8-Ks, investors can review information on research and development spending, general and administrative expenses, net loss, cash position and stockholders’ equity, as well as narrative descriptions of pipeline programs such as INB-100, INB-200, INB-400, INB-619 and the INB-600 platform. These filings also include risk factor discussions and forward-looking statements that frame the uncertainties inherent in clinical-stage biopharmaceutical development.
On Stock Titan, INAB filings are updated in line with new submissions to EDGAR. AI-powered tools can help summarize lengthy documents, highlight key clinical and financial disclosures, and surface specific items such as clinical trial updates embedded in exhibits to Form 8-K. Users interested in IN8bio’s regulatory and financial history can review this archive to track how the company describes its γδ T cell programs, manufacturing capabilities, Nasdaq listing status and other material developments over time.
IN8bio, Inc. is calling a virtual 2026 annual stockholder meeting on May 7, 2026, to elect two Class II directors, ratify CohnReznick LLP as auditor, and approve an Amended and Restated 2026 Equity Incentive Plan.
As of the March 18, 2026 record date, 9,847,089 shares of common stock were outstanding and entitled to vote. The new 2026 equity plan would authorize 4,054,937 shares for awards, including 2,920,000 new shares plus remaining and returning shares from prior plans, and features an automatic annual share increase formula tied to common shares and pre-funded warrants outstanding.
IN8bio, Inc. files its annual report describing a focused gamma‑delta T cell therapy pipeline alongside a going concern warning. The company is developing allogeneic and autologous gamma‑delta T cell products and T cell engagers for cancers and autoimmune diseases, highlighted by INB‑100 for high‑risk leukemias and INB‑200/INB‑400 for newly diagnosed glioblastoma.
Early clinical data show durable remissions in AML patients after haploidentical transplants and extended progression‑free survival in glioblastoma versus standard therapy. IN8bio reported cash of $27.1 million as of December 31 2025 and expects this to fund operations only into April 2027, leading management to state substantial doubt about its ability to continue as a going concern without additional capital or strategic transactions.
IN8bio, Inc. reported fourth quarter and full-year 2025 results, highlighting clinical progress in glioblastoma, a strengthened balance sheet and lower losses. Repeat dosing of its DeltEx DRI γδ T cells in newly diagnosed GBM achieved median progression-free survival of 13.0 months versus 6.6 months for a standard-of-care cohort, with no dose-limiting toxicities or serious unexpected safety issues reported.
The company closed an initial $20.1 million tranche of a private placement of up to $40.2 million, with net proceeds of $18.5 million expected to extend its cash runway into the first half of 2027. Cash was $27.1 million as of December 31, 2025, up from $11.1 million a year earlier. Full-year net loss narrowed to $19.4 million, or $4.44 per share, from $30.4 million, or $17.05 per share, driven by lower R&D and G&A expenses.
IN8bio is advancing its INB-200/400 GBM programs, INB-100 for high-risk leukemias, and the INB-600 γδ T cell engager platform, including INB-619 heading into IND-enabling studies. The company outlined multiple 2026 milestones, including FDA guidance on regulatory pathways, additional GBM data and initial INB-619 animal data.
IN8BIO, Inc. reports that Laurence W. Lytton and the Lytton-Kambara Foundation each beneficially own 9.99% of Common Stock, consisting of 984,031 shares reported for each holder.
The filing states that the reported holdings "consist of 900,000 shares of Common Stock and warrants to purchase 1,092,753 shares of Common Stock, subject to a 9.99% beneficial ownership limitation," and that the percentage was calculated based on 9,766,132 shares outstanding as of January 12, 2026, per a prospectus dated January 28, 2026.
IN8bio, Inc. reported that director Alan S. Roemer has notified the Board of his decision to resign from the Board and from the Audit and Compensation Committees, effective February 28, 2026. The company states that his resignation is not due to any disagreement with IN8bio, its management, the Board, or any Board committee on matters related to operations, policies, or practices.
The Board has appointed independent director Jeremy Graff as Interim Chair of the Board, effective the same date. This change reflects a governance and leadership transition at the Board level without any financial results or major transactions described in this report.
IN8bio, Inc. received a Schedule 13G showing that Alyeska Investment Group, Alyeska Fund GP, and Anand Parekh beneficially own 966,381 shares of common stock, representing 9.9% of the class as of December 31, 2025. The group reports no sole voting or dispositive power, but shared power over all reported shares.
The filing explains that Alyeska-related entities hold common stock, PIPE shares, and warrants, but the warrants are subject to a 9.9% ownership cap. Based on 9,761,425 IN8bio shares outstanding, the reporting persons certify the holdings were acquired in the ordinary course and not to influence control.
IN8bio, Inc. announced that its Board of Directors appointed Chief Operating Officer Kate Rochlin as President of the company, effective February 4, 2026. She will hold both roles of President and Chief Operating Officer, providing continuity in executive leadership. The company notes that there are no family relationships or related-party transactions involving Dr. Rochlin that require disclosure under the SEC’s executive and related-party rules.
IN8bio, Inc. (INAB) reported an option grant to executive Lawrence Lamb, EVP and CSO. On February 4, 2026, he received 72,000 employee stock options with a $1.96 exercise price, all held directly. Twenty-five percent vest on February 4, 2027, with the remaining options vesting in 36 equal monthly installments, contingent on his continued service.
IN8bio, Inc. (INAB) granted its Chief Financial Officer, McCall Patrick, a new stock option award. On February 4, 2026, the CFO received an employee stock option to purchase 75,000 shares of common stock at an exercise price of $1.96 per share.
These options were awarded at no cost and are held directly. Twenty-five percent of the shares vest on February 4, 2027, and the remaining shares vest in 36 equal monthly installments afterward, as long as the CFO continues to provide service through each vesting date.